Full metadata record
DC FieldValueLanguage
dc.contributor.authorYang, Yun-Liangen_US
dc.contributor.authorLin, Yi-Hsuanen_US
dc.contributor.authorTsao, Ming-Yangen_US
dc.contributor.authorChen, Chia-Geunen_US
dc.contributor.authorShih, Hsin-Ien_US
dc.contributor.authorFan, Jen-Chengen_US
dc.contributor.authorWang, Jang-Shiunen_US
dc.contributor.authorLo, Hsiu-Jungen_US
dc.date.accessioned2014-12-08T15:16:12Z-
dc.date.available2014-12-08T15:16:12Z-
dc.date.issued2006-07-13en_US
dc.identifier.issn1471-2199en_US
dc.identifier.urihttp://dx.doi.org/10.1186/1471-2199-7-22en_US
dc.identifier.urihttp://hdl.handle.net/11536/12031-
dc.description.abstractBackground: In the past decades, the prevalence of candidemia has increased significantly and drug resistance has also become a pressing problem. Overexpression of CDR1, an efflux pump, has been proposed as a major mechanism contributing to the drug resistance in Candida albicans. It has been demonstrated that biological fluids such as human serum can have profound effects on antifungal pharmacodynamics. The aim of this study is to understand the effects of serum in drug susceptibility via monitoring the activity of CDR1 promoter of C. albicans. Results: The wild-type C. albicans cells ( SC5314) but not the cdr1/cdr1 mutant cells became more susceptible to the antifungal drug when the medium contained serum. To understand the regulation of CDR1 in the presence of serum, we have constructed CDR1 promoter-Renilla luciferase ( CDR1p-RLUC) reporter to monitor the activity of the CDR1 promoter in C. albicans. As expected, the expression of CDR1p-RLUC was induced by miconazole. Surprisingly, it was repressed by serum. Consistently, the level of CDR1 mRNA was also reduced in the presence of serum but not N-acetyl-D-glucosamine, a known inducer for germ tube formation. Conclusion: Our finding that the expression of CDR1 is repressed by serum raises the question as to how does CDR1 contribute to the drug resistance in C. albicans causing candidemia. This also suggests that it is important to re-assess the prediction of in vivo therapeutic outcome of candidemia based on the results of standard in vitro antifungal susceptibility testing, conducted in the absence of serum.en_US
dc.language.isoen_USen_US
dc.titleSerum repressing efflux pump CDR1 in Candida albicansen_US
dc.typeArticleen_US
dc.identifier.doi10.1186/1471-2199-7-22en_US
dc.identifier.journalBMC MOLECULAR BIOLOGYen_US
dc.citation.volume7en_US
dc.citation.issueen_US
dc.citation.epageen_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.identifier.wosnumberWOS:000239772000001-
dc.citation.woscount13-
Appears in Collections:Articles


Files in This Item:

  1. 000239772000001.pdf